Article
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
The Journal of pharmacology and experimental therapeutics - 1 Oct 2011
Mitra Amit K, Crews Kristine R, Pounds Stanley, Cao Xueyuan, Feldberg Tanya, Ghodke Yogita, Gandhi Varsha, Plunkett William, Dolan M Eileen, Hartford Christine, Raimondi Susana, Campana Dario, Downing James, Rubnitz Jeffrey E, Ribeiro Raul C, Lamba Jatinder K
Abstract excerpt
Cytosolic 5'-nucleotidase II (NT5C2) is involved in the development of 1-β-d-arabinofuranosylcytosine (ara-C) resistance and has been associated with clinical outcome in patients receiving ara-C-based chemotherapy. NT5C2 inactivates ara-C by dephosphorylating ara-C monophosphate to ara-C. In this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.